An observational study in X-Linked Myotubular Myopathy, sponsored by Astellas Gene Therapies. Recruiting at 11 sites in 3 countries. Open to male participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Astellas Gene Therapies (part of Astellas Pharma Inc) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Myopathies, Structural, Congenital with a site in United States — 4 open to participants now, 6 under way, 1 of them phase 3. Myopathies, Structural, Congenital · United States.
Among the 13 studies in Myopathies, Structural, Congenital with a site in United States, this one is one of 3 that started in 2025, is one of 8 observational ones, and was the 10th registered.
24 studies on the registry are indexed under Myopathies, Structural, Congenital; 10 are open to participants now.
Browse Myopathies, Structural, Congenital studies →4 of the 13 studies in Myopathies, Structural, Congenital with a site in United States are open now. Recruiting first, the newest first:
Astellas Gene Therapies · Sites in United States, Canada
Ages up to 36 mo · Men only
Boston Children's Hospital · Sites in United States
University of Nevada, Las Vegas · Sites in United States
Ages 18–29
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Myopathies, Structural, Congenital studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.
This study: Up to 17 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is close to the median of 49 across 12 observational studies indexed under Myopathies, Structural, Congenital.
Median enrollment 27 across the 5 interventional studies, 41 across the 8 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 13 have an industry lead sponsor. The 8 most frequent:
This study is registered under Astellas Gene Therapies, one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Gene Therapies is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Astellas Pharma Inc has 6 studies filed under Myopathies, Structural, Congenital — fewer than ten, so there is no comparison to draw.
1 of the studies in Myopathies, Structural, Congenital with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07052929Astellas Gene TherapiesStudy of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Myopathies, Structural, Congenital with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
XLMTM (X-linked myotubular myopathy) is a serious genetic muscle condition. It is caused by changes in the MTM1 gene which stops or slows down normal muscle development, causing severe muscle weakness. There is currently no cure for XLMTM. Ongoing care is needed to manage symptoms and prevent further medical problems from this condition.
Recent research shows that individuals with XLMTM often have reduced bile flow which can affect liver and gallbladder health. Bile is a liquid made in the liver that helps digest fat. Ongoing liver health checks may help with the routine care of people with XLMTM.
There is a need to understand liver problems that develop in individuals with XLMTM over time. The main aim of the study is to learn how many boys with XLMTM have new cases of liver problems during the study.
This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the study sponsor (Astellas).
In this study, boys under 18 diagnosed with XLMTM will be followed for about 1 year. The health of their liver and gallbladder will be checked about every 6 weeks. This can be done at home, if preferred. A scan called a Fibroscan (also known as transient elastography) will check for signs of scarring in the liver (fibrosis) and the build-up of lipids. It is suggested that each boy will have a Fibroscan when they start the study and another scan when they complete the study.
This study will help understand liver, gallbladder, and bile duct issues in individuals with XLMTM over time. The goal is to improve their care and provide information to use in future clinical studies.
Approximately 50 male participants \< 18 years of age with genetically confirmed XLMTM will be enrolled at specialist sites.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pediatric and adolescent participants with XLMTM.
Other: No Intervention
No investigational drug will be administered to participants in this study.
Incidence rate of cholestasis
Calculated as the number of new cases of cholestasis over 48 weeks divided by total duration of follow-up for enrolled participants.
Time frame: Up to Week 48
Point prevalence of cholestasis
Point prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis prior to Day 1 (baseline).
Time frame: Day 1
Prevalence of cholestasis
Prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis within 1 year of Day 1 (baseline).
Time frame: Up to 1 year
Genetic variants of MTM1
The association between genetic variants of MTM1 and cholestasis will be evaluated.
Time frame: Up to Week 48
Risk of cholestasis temporarily associated with environmental modifiers
Medication use, immunization history, infectious disease history and dietary habits will be collected.
Time frame: Up to Week 48
Hospitalizations
Frequency and reason for hospitalizations will be collected.
Time frame: Up to Week 48
Duration of Hospitalizations
Duration of hospitalization visits will be collected.
Time frame: Up to Week 48
Emergency room visits
Frequency and reason for visit will be collected.
Time frame: Up to Week 48
Hepatology specialist visits
Frequency and reason for visit will be collected.
Time frame: Up to Week 48
Scheduled/unscheduled office visits
Frequency and reason for visit will be collected.
Time frame: Up to Week 48
Non-study-specified home healthcare visits
Frequency and reason for visit will be collected.
Time frame: Up to Week 48
Surgeries/procedures
Frequency and type will be collected.
Time frame: Up to Week 48
Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Dec 2027, 31 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Myopathies, Structural, Congenital →